China SXT Pharmaceuticals Schedules 2025 Special Shareholder Meeting

Ticker: SXTC · Form: 6-K · Filed: Jul 15, 2025 · CIK: 1723980

China Sxt Pharmaceuticals, Inc. 6-K Filing Summary
FieldDetail
CompanyChina Sxt Pharmaceuticals, Inc. (SXTC)
Form Type6-K
Filed DateJul 15, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: shareholder-meeting, corporate-action, filing

TL;DR

SXT calling a special shareholder meeting on July 15, 2025 - expect news soon.

AI Summary

China SXT Pharmaceuticals, Inc. filed a Form 6-K on July 15, 2025, to furnish documents related to its 2025 special meeting of shareholders. The filing includes the Notice of the 2025 Special Meeting of Shareholders as Exhibit 99.1.

Why It Matters

This filing signals upcoming corporate actions or decisions that could impact the company's strategic direction and shareholder value.

Risk Assessment

Risk Level: low — The filing is procedural, announcing a shareholder meeting, and does not contain material financial or operational changes.

Key Players & Entities

  • China SXT Pharmaceuticals, Inc. (company) — Registrant
  • 2025 (date) — Special Meeting Year
  • July 15, 2025 (date) — Filing Date
  • Exhibit 99.1 (document) — Notice of Special Meeting

FAQ

What is the purpose of the 2025 special meeting of shareholders for China SXT Pharmaceuticals, Inc.?

The purpose is to address matters requiring shareholder approval, as indicated by the furnishing of the Notice of 2025 Special Meeting of Shareholders.

When was this Form 6-K filed with the SEC?

This Form 6-K was filed on July 15, 2025.

What is the primary document furnished with this 6-K filing?

The primary document furnished is the Notice of 2025 Special Meeting of Shareholders, designated as Exhibit 99.1.

Under which rule is China SXT Pharmaceuticals, Inc. filing this report?

The company is filing this report pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

What is the principal executive office address of China SXT Pharmaceuticals, Inc.?

The principal executive office is located at 178 Taidong Rd North, Taizhou Jiangsu, China.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on July 15, 2025 regarding China SXT Pharmaceuticals, Inc. (SXTC).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.